BRPI0607529B8 - compostos azol e composições farmacêuticas compreendendo os mesmos - Google Patents
compostos azol e composições farmacêuticas compreendendo os mesmosInfo
- Publication number
- BRPI0607529B8 BRPI0607529B8 BRPI0607529A BRPI0607529A BRPI0607529B8 BR PI0607529 B8 BRPI0607529 B8 BR PI0607529B8 BR PI0607529 A BRPI0607529 A BR PI0607529A BR PI0607529 A BRPI0607529 A BR PI0607529A BR PI0607529 B8 BRPI0607529 B8 BR PI0607529B8
- Authority
- BR
- Brazil
- Prior art keywords
- azole compounds
- same
- pharmaceutical compositions
- stroke
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D257/04—Five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Child & Adolescent Psychology (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Anesthesiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US67453005P | 2005-04-22 | 2005-04-22 | |
| US60/674,530 | 2005-04-22 | ||
| PCT/KR2006/001523 WO2006112685A1 (en) | 2005-04-22 | 2006-04-21 | Neurotherapeutic azole compounds |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BRPI0607529A2 BRPI0607529A2 (pt) | 2009-09-15 |
| BRPI0607529B1 BRPI0607529B1 (pt) | 2021-05-18 |
| BRPI0607529B8 true BRPI0607529B8 (pt) | 2021-05-25 |
Family
ID=37115369
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0607529A BRPI0607529B8 (pt) | 2005-04-22 | 2006-04-21 | compostos azol e composições farmacêuticas compreendendo os mesmos |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US7598279B2 (https=) |
| EP (1) | EP1879873B1 (https=) |
| JP (1) | JP5035238B2 (https=) |
| KR (1) | KR101286499B1 (https=) |
| CN (1) | CN101228138B (https=) |
| AR (1) | AR053065A1 (https=) |
| AU (1) | AU2006237798B2 (https=) |
| BE (1) | BE2021C524I2 (https=) |
| BR (1) | BRPI0607529B8 (https=) |
| CA (1) | CA2606258C (https=) |
| DK (1) | DK1879873T3 (https=) |
| ES (1) | ES2441765T3 (https=) |
| FI (1) | FIC20210018I1 (https=) |
| FR (1) | FR21C1027I2 (https=) |
| MX (1) | MX2007013197A (https=) |
| MY (1) | MY148589A (https=) |
| NL (1) | NL301106I2 (https=) |
| PL (1) | PL1879873T3 (https=) |
| PT (1) | PT1879873E (https=) |
| RU (1) | RU2418792C2 (https=) |
| TW (1) | TWI398249B (https=) |
| WO (1) | WO2006112685A1 (https=) |
| ZA (1) | ZA200709994B (https=) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7598279B2 (en) | 2005-04-22 | 2009-10-06 | Sk Holdings Co., Ltd. | Neurotherapeutic azole compounds |
| ES2379848T3 (es) * | 2007-05-14 | 2012-05-04 | Sk Biopharmaceuticals Co., Ltd. | Compuesto arilpiperazina arilalcanoil carbomoiloxi novedoso, composiciones farmacéuticas que comprenden el compuesto y método para tratar el dolor, ansiedad y depresión al administrar el compuesto |
| AU2008258599B2 (en) | 2007-06-05 | 2013-06-13 | Nsab, Filial Af Neurosearch Sweden Ab, Sverige | Disubstituted phenylpyrrolidines as modulators of cortical catecholaminergic neurotransmission |
| JP5527668B2 (ja) * | 2008-06-05 | 2014-06-18 | エスケー バイオファーマスティカルズ カンパニー リミテッド | ３−置換プロパンアミン化合物 |
| PL2445890T3 (pl) | 2009-06-22 | 2016-02-29 | Sk Biopharmaceuticals Co Ltd | Sposób wytwarzania estru (R)-1-arylo-2-tetrazoliloetylowego kwasu karbaminowego |
| US8404461B2 (en) * | 2009-10-15 | 2013-03-26 | SK Biopharmaceutical Co. Ltd. | Method for preparation of carbamic acid (R)-1-aryl-2-tetrazolyl-ethyl ester |
| MX350745B (es) | 2009-11-06 | 2017-09-14 | Sk Biopharmaceuticals Co Ltd * | El uso de un compuesto de carbamoilo para el tratamiento del sindrome de fibromialgia. |
| US8895609B2 (en) | 2009-11-06 | 2014-11-25 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating attention-deficit/hyperactivity disorder |
| US8623913B2 (en) | 2010-06-30 | 2014-01-07 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating restless legs syndrome |
| US9610274B2 (en) | 2010-06-30 | 2017-04-04 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating bipolar disorder |
| ES2802251T3 (es) * | 2012-01-06 | 2021-01-18 | Novartis Ag | Compuestos heterocíclicos y métodos para su uso |
| US9630896B2 (en) | 2013-11-22 | 2017-04-25 | Tansna Therapeutics, Inc. | 2,5-dialkyl-4-H/halo/ether-phenol compounds |
| TWI698415B (zh) * | 2014-02-28 | 2020-07-11 | 南韓商愛思開生物製藥股份有限公司 | 胺基羰基胺基甲酸酯化合物 |
| ITUA20161941A1 (it) * | 2016-03-23 | 2017-09-23 | Univ Degli Studi Di Siena | Uso di derivati dell’acido 2-amminotiofen-3- carbossilico per il trattamento delle dipendenze da cibo |
| KR102421013B1 (ko) | 2016-05-19 | 2022-07-14 | 에스케이바이오팜 주식회사 | 삼차신경통을 예방 또는 치료하기 위한 카바메이트 화합물의 용도 |
| KR102421006B1 (ko) | 2016-05-19 | 2022-07-14 | 에스케이바이오팜 주식회사 | 두통의 예방학적 치료를 위한 카바메이트 화합물의 용도 |
| KR102489052B1 (ko) * | 2016-05-19 | 2023-01-16 | 에스케이바이오팜 주식회사 | 섬유근육통 또는 섬유근육통의 연관된 기능적 증후군을 예방 또는 치료하기 위한 카바메이트 화합물의 용도 |
| MX391363B (es) * | 2016-12-14 | 2025-03-21 | Sk Biopharmaceuticals Co Ltd | Uso de compuesto de carbamato para prevenir, aliviar o tratar temblores o el sindrome de temblor. |
| KR102900173B1 (ko) * | 2016-12-14 | 2025-12-12 | 에스케이바이오팜 주식회사 | 조현병, 강박장애 및 투렛증후군으로부터 선택되는 정신증 장애의 예방, 경감 또는 치료에 있어서의 카바메이트 화합물의 용도 |
| KR102635938B1 (ko) | 2016-12-14 | 2024-02-13 | 에스케이바이오팜 주식회사 | 양극성 장애의 예방, 경감 또는 치료를 위한 카바메이트 화합물의 용도 |
| PL3556349T3 (pl) | 2016-12-14 | 2022-04-11 | Sk Biopharmaceuticals Co., Ltd. | Preparat ciekły do podawania pozajelitowego zawierający związek karbaminianowy |
| ES3035674T3 (en) | 2016-12-14 | 2025-09-08 | Sk Biopharmaceuticals Co Ltd | Use of carbamate compound for prevention, alleviation, or treatment of demyelinating disease |
| US12409164B2 (en) * | 2016-12-14 | 2025-09-09 | Sk Biopharmaceuticals Co., Ltd. | Orally disintegrated tablet comprising carbamate compound |
| WO2018111003A1 (ko) | 2016-12-14 | 2018-06-21 | 에스케이바이오팜 주식회사 | 가려움증의 예방, 경감 또는 치료를 위한 카바메이트 화합물의 용도 |
| KR102901908B1 (ko) * | 2016-12-14 | 2025-12-17 | 에스케이바이오팜 주식회사 | 운동신경세포 질환의 예방, 경감 또는 치료를 위한 카바메이트 화합물의 용도 |
| MX2020004972A (es) | 2017-11-14 | 2020-08-24 | Sk Biopharmaceuticals Co Ltd | Uso de compuesto de carbamato para prevenir, aliviar o tratar ataque de ausencia o epilepsia que muestra ataque de ausencia. |
| MX2020004975A (es) * | 2017-11-14 | 2020-08-24 | Sk Biopharmaceuticals Co Ltd | Mezcla que contiene compuesto de carbamato para prevencion, mitigacion o tratamiento de esquizofrenia. |
| EP3711756A4 (en) | 2017-11-14 | 2021-11-24 | SK Biopharmaceuticals Co., Ltd. | USE OF A CARBAMATE COMPOUND TO PREVENT, RELAX, OR TREAT MYOTONIA |
| EP3711761A4 (en) * | 2017-11-14 | 2021-11-24 | SK Biopharmaceuticals Co., Ltd. | USE OF A CARBAMATE COMPOUND TO REDUCE OR TREAT DEVELOPMENTAL DISORDERS, INCLUDING FRAGILE X SYNDROME, ANGELMAN'S SYNDROME, OR RETT'S SYNDROME |
| ES3027977T3 (en) * | 2017-11-14 | 2025-06-17 | Sk Biopharmaceuticals Co Ltd | Use of a carbamate compound to prevent, alleviate or treat visceralgia or pain arising from visceral disease |
| EP3711760B1 (en) * | 2017-11-14 | 2024-02-14 | SK Biopharmaceuticals Co., Ltd. | Use of carbamate compound for preventing or treating diseases associated with increase in late sodium current |
| US20220117941A1 (en) * | 2018-09-21 | 2022-04-21 | Sk Biopharmaceuticals Co., Ltd. | Carbamate compound and use of formulation comprising same in preventing, alleviating, or treating acute stress disorder or post-traumatic stress disorder |
| WO2020060252A1 (ko) | 2018-09-21 | 2020-03-26 | 에스케이바이오팜 주식회사 | 중첩발작의 예방, 경감 또는 치료에 대한 카바메이트 화합물의 용도 |
| TWI826531B (zh) * | 2018-09-21 | 2023-12-21 | 南韓商愛思開生物製藥股份有限公司 | 具有㗁二唑之化合物及包含該化合物之醫藥組合物 |
| JP7369185B2 (ja) * | 2018-10-19 | 2023-10-25 | エスケー バイオファーマスティカルズ カンパニー リミテッド | カルバメート化合物の糖尿病性末梢神経障害又は化学療法剤誘発性末梢神経障害の予防、緩和又は治療のための使用 |
| US10611737B1 (en) | 2019-10-24 | 2020-04-07 | Sk Biopharmaceuticals Co., Ltd. | Method for preparing aryl 2-tetrazol-2-yl ketone with improved selectivity |
| JP7724776B2 (ja) * | 2019-11-22 | 2025-08-18 | エスケー バイオファーマスティカルズ カンパニー リミテッド | カルバメート化合物を含む経口用医薬組成物及びその製造方法 |
| EP4193987A4 (en) * | 2020-08-06 | 2024-08-21 | SK Biopharmaceuticals Co., Ltd. | SOLID ORAL COMPOSITION COMPRISING A CARBAMATE COMPOUND AND PROCESS FOR ITS PREPARATION |
| CN114317620B (zh) * | 2020-09-29 | 2024-02-02 | 上海医药工业研究院 | 一种(r)-2-(2-氯苯基)环氧乙烷的生物制备方法 |
| AR125970A1 (es) | 2021-05-28 | 2023-08-30 | Sk Biopharmaceuticals Co Ltd | Formulaciones de suspensión acuosa para administración oral que comprenden un compuesto de carbamato |
| CN115974799B (zh) * | 2021-10-14 | 2024-08-13 | 成都百裕制药股份有限公司 | 氨基甲酸酯取代的醇衍生物及其在医药上的应用 |
| ES2931000B2 (es) * | 2022-07-14 | 2023-07-07 | Univ Madrid Complutense | Proceso para la preparación de cenobamato |
| CN115716810B (zh) * | 2022-11-15 | 2026-02-13 | 江苏艾立康医药科技有限公司 | 一种西诺氨酯的晶体形式及其制备方法 |
| CN118239901A (zh) * | 2023-03-15 | 2024-06-25 | 江苏恩华药业股份有限公司 | 一种氨基甲酸(r)-1-(2-氯苯基)-2-四唑-2-基乙酯的晶体 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3415840A (en) | 1965-10-22 | 1968-12-10 | American Home Prod | Pyrazole-1-ethanol derivatives |
| DK181988A (da) | 1988-03-30 | 1989-10-01 | Dumex Ltd As | Thiocarbamidsyreester til brug som terapeutikum samt praeparat til behandling af alkoholmisbrug |
| HU221190B1 (en) * | 1991-08-22 | 2002-08-28 | Warner Lambert Co | Acyl-coenzyme-a-cholesterol-acyl-transferase (acat) inhibitor tetrazole-carboxamide derivatives |
| MXPA04000008A (es) * | 2001-06-25 | 2004-05-21 | Sk Corp | Carbamatos de 2-heterociclic-1,2-etanodioles. |
| US6770659B2 (en) * | 2002-08-26 | 2004-08-03 | Sk Corporation | Benzoyl piperidine compounds |
| US7598279B2 (en) | 2005-04-22 | 2009-10-06 | Sk Holdings Co., Ltd. | Neurotherapeutic azole compounds |
-
2006
- 2006-04-20 US US11/407,526 patent/US7598279B2/en active Active
- 2006-04-21 WO PCT/KR2006/001523 patent/WO2006112685A1/en not_active Ceased
- 2006-04-21 ES ES06768472.0T patent/ES2441765T3/es not_active Expired - Lifetime
- 2006-04-21 CA CA2606258A patent/CA2606258C/en not_active Expired - Lifetime
- 2006-04-21 RU RU2007143073/04A patent/RU2418792C2/ru active
- 2006-04-21 KR KR1020077026985A patent/KR101286499B1/ko not_active Expired - Lifetime
- 2006-04-21 JP JP2008507557A patent/JP5035238B2/ja not_active Expired - Lifetime
- 2006-04-21 MX MX2007013197A patent/MX2007013197A/es active IP Right Grant
- 2006-04-21 AU AU2006237798A patent/AU2006237798B2/en not_active Expired
- 2006-04-21 PT PT67684720T patent/PT1879873E/pt unknown
- 2006-04-21 AR ARP060101598A patent/AR053065A1/es active IP Right Grant
- 2006-04-21 DK DK06768472.0T patent/DK1879873T3/da active
- 2006-04-21 TW TW095114655A patent/TWI398249B/zh active
- 2006-04-21 EP EP06768472.0A patent/EP1879873B1/en not_active Expired - Lifetime
- 2006-04-21 BR BRPI0607529A patent/BRPI0607529B8/pt active IP Right Grant
- 2006-04-21 CN CN2006800134724A patent/CN101228138B/zh not_active Expired - Lifetime
- 2006-04-21 PL PL06768472T patent/PL1879873T3/pl unknown
- 2006-04-24 MY MYPI20061865A patent/MY148589A/en unknown
-
2007
- 2007-11-20 ZA ZA200709994A patent/ZA200709994B/xx unknown
-
2021
- 2021-05-31 NL NL301106C patent/NL301106I2/nl unknown
- 2021-06-14 FI FIC20210018C patent/FIC20210018I1/fi unknown
- 2021-06-28 BE BE2021C524C patent/BE2021C524I2/nl unknown
- 2021-07-06 FR FR21C1027C patent/FR21C1027I2/fr active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0607529B8 (pt) | compostos azol e composições farmacêuticas compreendendo os mesmos | |
| WO2009035473A3 (en) | Method of treating binge eating disorder, obesity resulting from binge eating behavior and depressive disorders | |
| BRPI0918868B8 (pt) | compostos moduladores do receptor de nmda e composições compreendendo os mesmos | |
| BRPI1011220A2 (pt) | composição farmacêutica, métodos para tratar uma doença ou distúrbio, para administração respiratória de dois ou mais agentes ativos, para administração respiratória de uma combinação de agentes ativos, e, para preparar uma composição adequada. | |
| WO2007137247A3 (en) | Treatment for depressive disorders | |
| WO2008021113A3 (en) | Transdermal methods and systems for treating alzheimer's disease | |
| BR112014009851A2 (pt) | moduladores de receptor de nmda e usos dos mesmos | |
| WO2007025286A3 (en) | Therapy procedure for drug delivery for trigeminal pain | |
| MX2011001384A (es) | Composiciones y metodos para tratar trastornos psiquiatricos. | |
| CL2008002246A1 (es) | Uso de compuestos derivados de benzamida para tratar trastornos del sistema nervioso central seleccionados entre depresion, ansiedad trastornos psicoticos, trastornos neurologicos, epilepsia, trastornos cardiovasculares, diabetes, dislipidemias, entre otros; compuestos derivados de benzamida; composicion farmaceutica; y uso de la composicion. | |
| DK1656122T4 (da) | Transdermale lægemiddeltilberedninger med kombinationer af aktive stoffer til behandling af Parkinsons syge | |
| CL2011000043A1 (es) | Compuestos derivados de benzoazepina sustituidos; compuestosintermediarios; metodo de sintesis; composicion farmaceutica; y uso en el tratamiento o prevencion de un trastorno del sistema nervioso central. | |
| CL2012001673A1 (es) | Compuestos derivados de benzamida sustituidos, como moduladores de taar; procedimiento de preparación; composición farmacéutica; y su uso en el tratamiento de la depresión, trastornos de ansiedad, trastorno bipolar, esquizofrenia, epilepsia, migraña, enfermedad de alzheimer, trastornos metabolicos, entre otras. | |
| UA109878C2 (uk) | Похідні ізохінолінону, фармацевтична композиція на їх основі (варіанти) та спосіб лікування захворювань (варіанти) | |
| UA110199C2 (xx) | Тверда дисперсія рифаксиміну | |
| UA96447C2 (ru) | Полиморфные формы (2s)-(4e)-n-метил-5-[3-(5-изопропоксипиридин)ил]-4-пентен-2-амина для лечения расстройств центральной нервной системы | |
| WO2008024371A3 (en) | Multimediator transporter inhibitors for use in treatment of central nervous system disorders | |
| BRPI0515528A (pt) | n-metil hidroxietilamina úteis no tratamento de condições do sistema nervoso central | |
| BRPI0410837A (pt) | composto, composição farmacêutica, e, método para tratar ou prevenir uma doença ou condição | |
| TW200716204A (en) | Pharmaceutical composition | |
| PE20011049A1 (es) | Combinacion de farmacos para el tratamiento de la depresion y trastornos relacionados que comprenden mirtazapina | |
| WO2008063311A3 (en) | Cyclic glycyl-2-allyl proline improves cognitive performance in impaired animals | |
| EP1603595A4 (en) | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF DRUG INDEPENDENCE | |
| DE602004016547D1 (de) | 1,4-dihydropyridinverbindungen, pharmazeutische verbindungen, und verfahren zur behandlung von herzkreislauferkrankungen | |
| DE602006009848D1 (de) | Die regeneration von neuronen des zentralen nervensystems stimulierende peptidsubstanz, darauf basierende pharmazeutische zusammensetzung und verfahren zu ihrer anwendung |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B06T | Formal requirements before examination [chapter 6.20 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B25A | Requested transfer of rights approved |
Owner name: SK BIOPHARMACEUTICALS CO., LTD. (KR) |
|
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 21/04/2006, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 21/04/2006 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |